This week, the United States Department of Justice announced that Abbott Laboratories Inc. has pleaded guilty to a criminal misdemeanor and has agreed to pay…
Read More »The FDA at times gives its stamp of approval to drugs that only work in small subset of the patient population. For example, a few…
Read More »In this era of mega international pharmaceutical mergers, pending False Claims Act lawsuits oftentimes bubble to the surface at the closing table. Recently, as Teva…
Read More »Recently, the US Department of Health & Human Services Office of Inspector General found that, in the six-month period from January through June 2007, an…
Read More »Anyone interested in off-label cases should review the retrospective analysis recently published by researchers funded by the Agency for Healthcare Research and Quality. In the…
Read More »In recent years, a number of drug companies have settled False Claims Act cases, alleging that the companies off-label marketed their products to children. Oftentimes,…
Read More »Kos Pharmaceuticals, a subsidiary of Abbott Laboratories, has agreed to pay $41 million to quiet criminal and civil allegations that it violated the federal anti-kickback…
Read More »On November 15, 2010, Scios, Inc. announced that the investigatory study of NATRECOR (ASCEND-HF trial) demonstrated no statistically significant difference from placebo in the co-primary…
Read More »Last month, drug company Allergan, Inc. agreed to pay $225 million to resolve civil allegations that it unlawfully promoted its drug Botox® Therapeutic for unapproved…
Read More »From time to time, pharmaceutical companies have challenged the reach of the FCA, especially as it is applies to off-label pharmaceutical marketing schemes. Last week,…
Read More »